美丽田园医疗健康(02373)发布公告，本公司进一步获中信产业投资基金管理有限公司(CPE)通知，其已 于2025年8月18日完成该公告所述股份出售。截至2025年8月18日，CPE已通过一系列交易，出售大部分 其所持有的本公司股份，CPE已不再作为本公司主要股东。 因CPE已不再作为本公司主要股东，胡腾鹤先生(胡先生)及耿嘉琦先生(耿先生)已决定辞去现任非执行 董事职务并已于2025年8月18日递交辞呈并于同日生效。 本公司获得国内外长线优质资金投入，新股东加入不仅带来丰富的产业资源协同与国际化视野，更通过 战略经验与资源网络的注入，为本公司业务拓展与资本市场价值提升增添新动能。 董事会欣然宣布，胡先生及耿先生辞任后，董事会委任高建明先生(高先生)及易琳女士(易女士)为非执 行董事，自2025年8月18日起生效。 作为早期投资人，CPE在本集团发展历程中提供了重要战略指导，助力本集团成功登陆资本市场。本公 司谨此向CPE致以诚挚感谢。 本次CPE退出对本公司股东结构调整有关键帮助，释放多重积极效应：一，私募股权基金股东平稳退 出，股权结构稳定性显著增强;二，引入背景多元的优质长期投资者，进一步完善公司治理体 ...

Core Viewpoint - The major shareholder of MicroPort Medical (0853.HK), Otsuka Medical Devices Co., Ltd. ("Otsuka"), plans to sell approximately 291 million shares, reducing its stake from 20.7% to 4.99%, with We'Tron becoming the largest shareholder post-transaction [3][5][6]. Group 1: Shareholder Changes - Otsuka has been the largest shareholder of MicroPort since 2013 and has decided to divest part of its stake to enhance long-term sustainable growth and company value [3][4]. - The transaction involves multiple buyers, including Shanghai Shanshi Capital Management Co., Ltd. and We'Tron, with Otsuka selling approximately 135 million shares to each [5][6]. - After the completion of the transaction, We'Tron's stake will increase from approximately 18.7% to an estimated 26%, making it the largest shareholder [6][8]. Group 2: Financial Performance - MicroPort reported a revenue of approximately $1.031 billion in 2024, a year-on-year increase of 9.6%, but incurred a loss of about $269 million [8]. - The company has faced five consecutive years of losses, with a net cash outflow of approximately $49.67 million in operating cash flow [8][10]. - As of the end of 2024, MicroPort's cash and cash equivalents were approximately $713 million, down by about $300 million from the end of 2023, with total borrowings around $1.597 billion [8][10]. Group 3: Financing and Debt Obligations - MicroPort is under pressure from a financing agreement that requires it to meet specific performance targets from 2024 to 2026, including limiting losses to $275 million in 2024 and achieving a net profit of at least $4.5 million in the first half of 2026 [9][10]. - The company has also faced challenges related to its subsidiaries, including a potential redemption risk for MicroPort Heart Management if it fails to go public by July 17, 2025 [11]. Group 4: Business Operations and Market Challenges - MicroPort's main business segments include cardiovascular intervention, orthopedic medical devices, and surgical robots, among others [10][11]. - The company has experienced losses in most of its business segments, with the surgical robot segment reporting a loss of approximately $90.93 million, although this was a 37.3% improvement compared to the previous year [11]. - Revenue declines have been attributed to geopolitical tensions, intense industry competition, and adjustments in product pricing due to healthcare policy changes [11].